JP2008500815A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008500815A5 JP2008500815A5 JP2007504185A JP2007504185A JP2008500815A5 JP 2008500815 A5 JP2008500815 A5 JP 2008500815A5 JP 2007504185 A JP2007504185 A JP 2007504185A JP 2007504185 A JP2007504185 A JP 2007504185A JP 2008500815 A5 JP2008500815 A5 JP 2008500815A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- pharmaceutical composition
- tumor
- antibody fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 14
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 6
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 6
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 6
- 229940034982 antineoplastic agent Drugs 0.000 claims 5
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 229940122558 EGFR antagonist Drugs 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 108010017622 Somatomedin Receptors Proteins 0.000 claims 1
- 102000004584 Somatomedin Receptors Human genes 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55455504P | 2004-03-19 | 2004-03-19 | |
| US60/554,555 | 2004-03-19 | ||
| US62426404P | 2004-11-02 | 2004-11-02 | |
| US60/624,264 | 2004-11-02 | ||
| PCT/US2005/009583 WO2005090407A1 (en) | 2004-03-19 | 2005-03-21 | Human anti-epidermal growth factor receptor antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008500815A JP2008500815A (ja) | 2008-01-17 |
| JP2008500815A5 true JP2008500815A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2010-05-27 |
| JP4734319B2 JP4734319B2 (ja) | 2011-07-27 |
Family
ID=34964896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007504185A Expired - Lifetime JP4734319B2 (ja) | 2004-03-19 | 2005-03-21 | ヒト抗上皮成長因子受容体抗体 |
Country Status (18)
Families Citing this family (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| US20030224001A1 (en) * | 1998-03-19 | 2003-12-04 | Goldstein Neil I. | Antibody and antibody fragments for inhibiting the growth of tumors |
| ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
| CN1200734C (zh) * | 1999-05-14 | 2005-05-11 | 伊姆克罗尼系统公司 | 用表皮生长因子拮抗物治疗顽固性的人肿瘤 |
| EP1311291A4 (en) * | 2000-08-09 | 2007-07-25 | Imclone Systems Inc | TREATMENT OF HYPERPROLIFERATIVE DISEASES USING EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS |
| US20080008704A1 (en) * | 2001-03-16 | 2008-01-10 | Mark Rubin | Methods of treating colorectal cancer with anti-epidermal growth factor antibodies |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| JP2006519763A (ja) * | 2002-11-08 | 2006-08-31 | アブリンクス エン．ヴェー． | 治療用ポリペプチドの投与法およびそのためのポリペプチド |
| US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
| US20060034845A1 (en) * | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
| BRPI0316092B8 (pt) * | 2002-11-08 | 2021-05-25 | Ablynx Nv | anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos |
| US20100003253A1 (en) * | 2002-11-08 | 2010-01-07 | Ablynx N.V. | Single domain antibodies directed against epidermal growth factor receptor and uses therefor |
| ES2551682T3 (es) * | 2002-11-08 | 2015-11-23 | Ablynx N.V. | Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos |
| EP1622941A2 (en) * | 2003-03-20 | 2006-02-08 | ImClone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
| AU2007212447B2 (en) * | 2006-02-03 | 2013-02-21 | Imclone Llc | IGF-IR antagonists as adjuvants for treatment of prostate cancer |
| CN101058609B (zh) * | 2006-05-26 | 2011-04-13 | 神州细胞工程有限公司 | 人源抗体及其表达 |
| AU2007260769A1 (en) * | 2006-06-14 | 2007-12-21 | Imclone Llc | Lyophilized formulations of anti-EGFR antibodies |
| US20090280503A1 (en) * | 2006-09-15 | 2009-11-12 | James Fiore | Method for detecting and treating skin disorders |
| US7820159B2 (en) * | 2006-10-31 | 2010-10-26 | Instiute of Virology of the Slovak Academy of Sciences | MN/CA IX and EGFR pathway inhibition |
| WO2009067242A2 (en) * | 2007-11-20 | 2009-05-28 | Imclone Llc | Co-crystal of antibody 11f8 fab fragment and egfr extracellular domain and uses thereof |
| AU2008346734A1 (en) * | 2008-01-03 | 2009-07-16 | The Scripps Research Institute | Antibody targeting through a modular recognition domain |
| WO2009105557A1 (en) * | 2008-02-20 | 2009-08-27 | Arizona Biomedical Research Commission | Use of therapeutic peptides for the treatment and prevention of cancer |
| DK2322221T3 (da) | 2008-08-05 | 2014-09-01 | Toray Industries | Farmaceutisk sammensætning til behandling og forebyggelse af cancer |
| WO2010016527A1 (ja) | 2008-08-05 | 2010-02-11 | 東レ株式会社 | 癌の検出方法 |
| US20100189651A1 (en) | 2009-01-12 | 2010-07-29 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| KR101108642B1 (ko) * | 2009-09-29 | 2012-02-09 | 주식회사 녹십자 | 표피 성장 인자 수용체에 특이적으로 결합하는 항체 |
| CN101704891B (zh) | 2009-11-11 | 2011-11-09 | 中国人民解放军军事医学科学院生物工程研究所 | 一种针对表皮生长因子受体的抗体及其编码基因与应用 |
| CN101875695B (zh) * | 2009-11-11 | 2012-07-04 | 中国人民解放军军事医学科学院生物工程研究所 | 一种抗体及其编码基因与应用 |
| CN101875696B (zh) | 2009-11-11 | 2012-02-08 | 中国人民解放军军事医学科学院生物工程研究所 | 一种抗体及其制备方法与应用 |
| CA2784498A1 (en) * | 2009-12-18 | 2011-06-23 | Sanofi | Novel antagonist antibodies and their fab fragments against gpvi and uses thereof |
| AU2011211682B2 (en) | 2010-02-04 | 2015-08-13 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| PT2532743E (pt) | 2010-02-04 | 2015-08-04 | Toray Industries | Composição farmacêutica para o tratamento e/ou a prevenção de cancro |
| MX2012008991A (es) | 2010-02-04 | 2012-09-07 | Toray Industries | Medicamento para tratar y/o prevenir el cancer. |
| KR101842893B1 (ko) | 2010-02-04 | 2018-03-28 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| KR101801667B1 (ko) | 2010-02-04 | 2017-11-27 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| WO2012018260A1 (en) * | 2010-08-05 | 2012-02-09 | Universiteit Utrecht Holding B.V. | Epidermal growth factor receptor targeted immune therapy |
| EP2614086A1 (en) | 2010-09-08 | 2013-07-17 | Halozyme, Inc. | Methods for assessing and identifying or evolving conditionally active therapeutic proteins |
| KR101273918B1 (ko) | 2010-09-17 | 2013-06-13 | 강원대학교산학협력단 | 인간 항-상피세포성 성장인자수용체 Ｆａｂ 항체 및 이를 포함하는 종양 치료용 약학 조성물 |
| CA2814670A1 (en) | 2010-10-12 | 2012-04-19 | Arizona Biomedical Research Commission | Egfr-based peptides |
| EP2632490A4 (en) | 2010-10-29 | 2014-10-22 | Immunogen Inc | NOVEL MOLECULES BINDING TO THE EGF RECEPTOR AND IMMUNOCONJUGATES THEREOF |
| CN103328505B (zh) | 2010-10-29 | 2015-12-02 | 伊缪诺金公司 | 非拮抗性egfr结合分子及其免疫偶联物 |
| US9428565B2 (en) | 2011-01-31 | 2016-08-30 | The General Hospital Corporation | Treatment and bioluminescent visualization using multimodal TRAIL molecules |
| TWI582112B (zh) | 2011-04-21 | 2017-05-11 | 西雅圖遺傳學公司 | 新穎結合劑－藥物接合物（ＡＤＣｓ）及其用途（二） |
| ES2704038T3 (es) | 2011-05-24 | 2019-03-13 | Zyngenia Inc | Complejos multiespecíficos multivalentes y monovalentes y sus usos |
| MX348579B (es) | 2011-08-04 | 2017-06-20 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| PT2740489T (pt) | 2011-08-04 | 2017-01-10 | Toray Industries | Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático |
| HUE033183T2 (en) | 2011-08-04 | 2017-11-28 | Toray Industries | A medicament for treating and / or preventing cancer |
| HUE047006T2 (hu) | 2011-08-04 | 2020-04-28 | Toray Industries | Anti-caprin-1 antitesteket tartalmazó gyógyászati kompozíció rák kezelésére és/vagy megelõzésére |
| CA2844040C (en) | 2011-08-04 | 2019-05-07 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| DK2740795T3 (en) | 2011-08-04 | 2017-01-16 | Toray Industries | Pharmaceutical composition for the treatment and / or prevention of cancer |
| CA2844033C (en) | 2011-08-04 | 2021-07-27 | Toray Industries, Inc. | Method for detecting pancreatic cancer |
| CA2856411A1 (en) | 2011-11-21 | 2013-05-30 | Immunogen, Inc. | Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate |
| CN104114581B (zh) | 2012-02-21 | 2018-11-30 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| AU2013223161B2 (en) | 2012-02-21 | 2017-10-19 | Toray Industries, Inc. | Medicinal composition for treating and/or preventing cancer |
| HUE045461T2 (hu) | 2012-02-21 | 2019-12-30 | Toray Industries | Gyógyászati készítmény rák kezelésére |
| WO2013125636A1 (ja) | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| JP6181089B2 (ja) | 2012-03-08 | 2017-08-16 | ハロザイム インコーポレイテッド | 条件依存活性抗上皮細胞増殖因子受容体抗体およびその使用方法 |
| ES2656501T3 (es) | 2012-03-30 | 2018-02-27 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la prevención de cáncer de vesícula biliar |
| PL2832365T3 (pl) | 2012-03-30 | 2018-04-30 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi wątroby |
| US9944707B2 (en) | 2012-05-17 | 2018-04-17 | Sorrento Therapeutics, Inc. | Antibodies that bind epidermal growth factor receptor (EGFR) |
| JP6103832B2 (ja) | 2012-06-25 | 2017-03-29 | Hoya株式会社 | Ｅｇｆｒ結合性ペプチド |
| WO2014014086A1 (ja) | 2012-07-19 | 2014-01-23 | 東レ株式会社 | 癌の検出方法 |
| WO2014014082A1 (ja) | 2012-07-19 | 2014-01-23 | 東レ株式会社 | 癌の検出方法 |
| EP2877572B1 (en) | 2012-07-24 | 2018-11-28 | The General Hospital Corporation | Oncolytic virus therapy for resistant tumors |
| EP2879712B1 (en) | 2012-07-31 | 2018-04-25 | Crown Bioscience, Inc. (Taicang) | Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug |
| US9605074B2 (en) * | 2012-08-30 | 2017-03-28 | The General Hospital Corporation | Multifunctional nanobodies for treating cancer |
| CN102993305B (zh) * | 2012-11-16 | 2015-05-13 | 上海赛伦生物技术有限公司 | 人源抗人表皮生长因子受体抗体及其编码基因与应用 |
| RU2652880C2 (ru) | 2013-04-07 | 2018-05-03 | Дженрикс (Шанхай) Байофармасертикал Ко., Лтд. | Антитело против рецептора эпидермального фактора роста |
| US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| MX360671B (es) | 2013-08-09 | 2018-11-13 | Toray Industries | Composición farmacéutica para el tratamiento y/o prevención del cáncer. |
| US20150071923A1 (en) | 2013-09-12 | 2015-03-12 | Ge Wei | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
| CN106029697B (zh) | 2013-12-20 | 2021-06-04 | 英特维特国际股份有限公司 | 具有经修饰的ch2-ch3序列的犬抗体 |
| PT3086814T (pt) | 2013-12-23 | 2020-09-04 | Bayer Pharma AG | Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp |
| EP3126398B1 (en) | 2014-03-03 | 2020-07-15 | Academia Sinica | Bi-specific antibodies and uses thereof |
| SG10201900455YA (en) * | 2014-07-24 | 2019-02-27 | Bluebird Bio Inc | Bcma chimeric antigen receptors |
| CN108251431B (zh) | 2015-03-05 | 2020-12-08 | 北京百特美博生物科技有限公司 | 双载体系统及其用途 |
| WO2016161440A2 (en) | 2015-04-03 | 2016-10-06 | Arizona Cancer Therapeutics, Llc | Egfr-based inhibitor peptides for combinatorial inactivation of erbb1, erbb2, and erbb3 |
| TW201703769A (zh) | 2015-05-08 | 2017-02-01 | 美國禮來大藥廠 | 用於癌症的組合療法 |
| SG11201710639YA (en) | 2015-06-22 | 2018-01-30 | Bayer Pharma AG | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
| CN107921288A (zh) | 2015-06-23 | 2018-04-17 | 拜耳医药股份有限公司 | Ksp抑制剂的靶向缀合物 |
| TW201716439A (zh) | 2015-07-20 | 2017-05-16 | 美國禮來大藥廠 | Ｈｅｒ３抗體 |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
| WO2017160568A1 (en) | 2016-03-16 | 2017-09-21 | Eli Lilly And Company | Combination therapy comprising the cdk4/6 inhibitor necitumumab and the egfr inhibitor abemaciclib for use in treating cancer |
| KR20180123047A (ko) | 2016-03-24 | 2018-11-14 | 바이엘 파마 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물 |
| CN109310781B (zh) | 2016-06-15 | 2024-06-18 | 拜耳制药股份公司 | 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc) |
| JP6695003B2 (ja) * | 2016-09-26 | 2020-05-20 | イムクローン・リミテッド・ライアビリティ・カンパニーＩｍｃｌｏｎｅ ＬＬＣ | 癌のための併用療法 |
| WO2018114804A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
| KR20190099250A (ko) | 2016-12-21 | 2019-08-26 | 바이엘 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물 |
| IL310558A (en) | 2016-12-21 | 2024-03-01 | Bayer Pharma AG | Drug-antibody conjugates with enzymatically cleavable groups |
| JP7072792B2 (ja) * | 2017-12-11 | 2022-05-23 | 国立大学法人神戸大学 | 二重特異性抗体 |
| KR20210116437A (ko) | 2018-11-20 | 2021-09-27 | 코넬 유니버시티 | 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도 |
| CN113603783B (zh) | 2018-12-21 | 2022-07-12 | 浙江时迈药业有限公司 | 蛋白酶可切割的双特异性抗体及其用途 |
| CA3124659A1 (en) * | 2018-12-25 | 2020-07-02 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an egfr inhibitor |
| AU2020368369A1 (en) | 2019-10-15 | 2022-05-12 | Eli Lilly And Company | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
| CN117186219B (zh) * | 2020-04-17 | 2024-07-12 | 珠海泰诺麦博制药股份有限公司 | 抗人神经生长因子的抗体 |
| CN116782932A (zh) * | 2020-08-05 | 2023-09-19 | 俄亥俄州国家创新基金会 | 衔接多肽及其使用方法 |
| PT4058474T (pt) * | 2020-08-20 | 2024-07-09 | A2 Biotherapeutics Inc | Composições e métodos para tratamento de cancros positivos para egfr |
| WO2022068870A1 (zh) | 2020-09-30 | 2022-04-07 | 中国科学院动物研究所 | 靶向egfr的嵌合抗原受体 |
| WO2022140670A2 (en) * | 2020-12-23 | 2022-06-30 | Phenomic Ai | Anti-activin antibodies and methods of using the same |
| TW202440550A (zh) | 2022-12-15 | 2024-10-16 | 瑞士商赫孚孟拉羅股份公司 | 用於癌症治療之組合療法 |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4186567A (en) | 1977-04-18 | 1980-02-05 | Hitachi Metals, Ltd. | Ornament utilizing rare earth-cobalt magnet |
| US4510924A (en) | 1980-07-10 | 1985-04-16 | Yale-New Haven Hospital, Inc. | Brachytherapy devices and methods employing americium-241 |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| US5866363A (en) | 1985-08-28 | 1999-02-02 | Pieczenik; George | Method and means for sorting and identifying biological information |
| US4816401A (en) | 1985-09-09 | 1989-03-28 | University Of Rochester | Serum free cell culture medium |
| CA1275922C (en) | 1985-11-28 | 1990-11-06 | Harunobu Amagase | Treatment of cancer |
| US4846782A (en) | 1986-03-14 | 1989-07-11 | Schering Corporation | Treatment of cancer with interferon and radiotherapy |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4763642A (en) | 1986-04-07 | 1988-08-16 | Horowitz Bruce S | Intracavitational brachytherapy |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1988009344A1 (en) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5470571A (en) | 1988-01-27 | 1995-11-28 | The Wistar Institute | Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425 |
| IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
| FI895955A7 (fi) | 1988-04-15 | 1989-12-13 | Protein Design Labs Inc | Il-2-reseptorispesifisiä "kimeerisiä" vasta-aineita |
| WO1989009825A1 (en) | 1988-04-16 | 1989-10-19 | Celltech Limited | Method for producing recombinant dna proteins |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| ES2133271T3 (es) | 1989-07-06 | 1999-09-16 | Univ California | Receptores para factores de crecimiento de fibroblastos. |
| US5705157A (en) | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP0525109A4 (en) | 1990-04-16 | 1993-06-30 | Rhone-Poulenc Rorer International (Holdings) Inc. | Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase |
| US5196446A (en) | 1990-04-16 | 1993-03-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Certain indole compounds which inhibit EGF receptor tyrosine kinase |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992015683A1 (en) | 1991-03-06 | 1992-09-17 | MERCK Patent Gesellschaft mit beschränkter Haftung | Humanized and chimeric monoclonal antibodies |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5559235A (en) | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
| ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| AU4025193A (en) | 1992-04-08 | 1993-11-18 | Cetus Oncology Corporation | Humanized C-erbB-2 specific antibodies |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| AU690528B2 (en) | 1992-12-04 | 1998-04-30 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| US5855885A (en) | 1993-01-22 | 1999-01-05 | Smith; Rodger | Isolation and production of catalytic antibodies using phage technology |
| US5550114A (en) | 1993-04-02 | 1996-08-27 | Thomas Jefferson University | Epidermal growth factor inhibitor |
| US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| US5840301A (en) | 1994-02-10 | 1998-11-24 | Imclone Systems Incorporated | Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors |
| US6448077B1 (en) | 1994-02-10 | 2002-09-10 | Imclone Systems, Inc. | Chimeric and humanized monoclonal antibodies specific to VEGF receptors |
| US6811779B2 (en) * | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
| US5861499A (en) | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
| RU2137762C1 (ru) | 1994-02-23 | 1999-09-20 | Пфайзер Инк. | 4-гетероциклил-замещенные производные хиназолина, фармацевтическая композиция |
| AU2096895A (en) | 1994-03-07 | 1995-09-25 | Sugen, Incorporated | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| HU221001B1 (hu) | 1994-03-17 | 2002-07-29 | Merck Patent Gmbh. | Egyláncú anti-EGFR Fv-k és anti-EGFR ellenanyagok |
| JP3249007B2 (ja) | 1994-03-17 | 2002-01-21 | 富士通株式会社 | 半導体装置、その特性評価方法及び設計方法 |
| US5656655A (en) | 1994-03-17 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase |
| US5869465A (en) | 1994-04-08 | 1999-02-09 | Receptagen Corporation | Methods of receptor modulation and uses therefor |
| US5468754A (en) | 1994-04-19 | 1995-11-21 | Bionumerik Pharmaceuticals, Inc. | 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof |
| US5604233A (en) | 1994-04-28 | 1997-02-18 | Bionumerik Pharmaceuticals, Inc. | Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof |
| US5626862A (en) | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| ATE208633T1 (de) * | 1994-09-16 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
| WO1996030347A1 (en) | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Quinazoline derivatives |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5663144A (en) | 1995-05-03 | 1997-09-02 | The Trustees Of The University Of Pennsylvania | Compounds that bind to p185 and methods of using the same |
| US5726181A (en) | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
| US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| EP0888349B1 (en) | 1996-01-23 | 2002-05-22 | Novartis AG | Pyrrolopyrimidines and processes for their preparation |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
| WO1997046684A1 (en) | 1996-06-06 | 1997-12-11 | University Of Massachusetts | Non-activated receptor complex proteins and uses thereof |
| AU2912997A (en) | 1996-06-24 | 1998-01-14 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
| US6004967A (en) | 1996-09-13 | 1999-12-21 | Sugen, Inc. | Psoriasis treatment with quinazoline compounds |
| DE69839338T2 (de) | 1997-02-05 | 2008-07-10 | Warner-Lambert Company Llc | Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation |
| US5942602A (en) | 1997-02-13 | 1999-08-24 | Schering Aktiengessellschaft | Growth factor receptor antibodies |
| US20030105057A1 (en) | 1997-03-19 | 2003-06-05 | Yale University | Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment |
| US5914269A (en) | 1997-04-04 | 1999-06-22 | Isis Pharmaceuticals, Inc. | Oligonucleotide inhibition of epidermal growth factor receptor expression |
| US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US20020173629A1 (en) * | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
| US6417168B1 (en) | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
| ZA200007412B (en) | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
| CZ20004224A3 (cs) * | 1998-05-15 | 2002-02-13 | Imclone Systems Incorporated | Neradioaktivně značený inhibitor proteinového tyrosinkinázového receptoru |
| CZ303899B6 (cs) | 1998-09-29 | 2013-06-19 | Wyeth Holdings Corporation | Substituovaný 3-kyanochinolin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem |
| US6344455B1 (en) | 1998-11-19 | 2002-02-05 | Warner-Lambert Company | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, and irreversible inhibitor of tyrosine kinases |
| US7396810B1 (en) | 2000-08-14 | 2008-07-08 | Oregon Health Sciences University | Compositions and methods for treating cancer by modulating HER-2 and EGF receptors |
| CN1200734C (zh) | 1999-05-14 | 2005-05-11 | 伊姆克罗尼系统公司 | 用表皮生长因子拮抗物治疗顽固性的人肿瘤 |
| EP1054018B1 (en) | 1999-05-18 | 2009-01-28 | Dyax Corp. | Fab fragment libraries and methods for their use |
| DE60042693D1 (de) * | 1999-08-27 | 2009-09-17 | Genentech Inc | Dosierung für die behandlung mit anti erbb2-antikörpern |
| EP1311291A4 (en) * | 2000-08-09 | 2007-07-25 | Imclone Systems Inc | TREATMENT OF HYPERPROLIFERATIVE DISEASES USING EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS |
| EP1343820A4 (en) * | 2000-10-13 | 2005-09-14 | Uab Research Foundation | ANTI-EPIDERMIC GROWTH FACTOR RECEPTOR SINGLE CHAIN ANTIBODY |
| AU2002239486A1 (en) | 2000-12-08 | 2002-06-18 | Uab Research Foundation | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
| WO2002087618A1 (fr) | 2001-04-27 | 2002-11-07 | Takeda Chemical Industries, Ltd. | Methode de prevention et de traitement du cancer |
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| CN1966525A (zh) * | 2001-06-13 | 2007-05-23 | 根马布股份公司 | 表皮生长因子受体(egfr)的人单克隆抗体 |
| DE10163459A1 (de) | 2001-12-21 | 2003-07-03 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor |
| KR20040077889A (ko) * | 2002-01-28 | 2004-09-07 | 메다렉스, 인코포레이티드 | 전립선 특이적 막 항원 (ｐｓｍａ)에 대한 인간모노클로날 항체 |
| WO2003075840A2 (en) | 2002-03-04 | 2003-09-18 | Imclone Systems Incorporated | Human antibodies specific to kdr and uses thereof |
| WO2003075947A1 (en) | 2002-03-08 | 2003-09-18 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of egfr transactivation inhibitors in human cancer |
| EP1501530B1 (en) * | 2002-03-21 | 2009-02-18 | Cayman Chemical Company | Prostaglandin f2 alpha analogs in combination with antimicrobial for treating glaucoma |
| US20050148607A1 (en) | 2002-06-03 | 2005-07-07 | Tsuyoshi Suzuki | Preventives and/or remedies for subjects with the expression or activation of her2 and/or egfr |
| WO2004005890A2 (en) * | 2002-07-03 | 2004-01-15 | The Trustees Of The University Of Pennsylvania | Compositions, methods and kits relating to anti-platelet autoantibodies and inhibitors thereof |
| DK1549344T3 (en) * | 2002-10-10 | 2015-04-07 | Merck Patent Gmbh | PHARMACEUTICAL COMPOSITION FOR ERB-B1 RECEPTORS |
| WO2005016970A2 (en) | 2003-05-01 | 2005-02-24 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| EP1493445A1 (en) * | 2003-07-04 | 2005-01-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibition of stress-induced ligand-dependent EGFR activation |
| EP2251357A1 (en) * | 2003-11-07 | 2010-11-17 | Ablynx N.V. | Camelidae single domain antibodies VHH directed against epidermal growth factor receptor and uses therefor |
| DE10355904A1 (de) * | 2003-11-29 | 2005-06-30 | Merck Patent Gmbh | Feste Formen von anti-EGFR-Antikörpern |
| CA2555791A1 (en) * | 2004-02-12 | 2005-08-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Highly concentrated liquid formulations of anti-egfr antibodies |
| TW200533339A (en) * | 2004-03-16 | 2005-10-16 | Bristol Myers Squibb Co | Therapeutic synergy of anti-cancer compounds |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| JP5835204B2 (ja) | 2012-12-20 | 2015-12-24 | 信越化学工業株式会社 | レジスト材料及びこれを用いたパターン形成方法 |
-
2005
- 2005-03-21 PT PT05732383T patent/PT1735348E/pt unknown
- 2005-03-21 RU RU2006137060/13A patent/RU2402569C2/ru not_active IP Right Cessation
- 2005-03-21 EP EP05732383A patent/EP1735348B1/en not_active Expired - Lifetime
- 2005-03-21 EP EP10176938A patent/EP2332990A1/en not_active Withdrawn
- 2005-03-21 CA CA2560305A patent/CA2560305C/en not_active Expired - Fee Related
- 2005-03-21 PL PL05732383T patent/PL1735348T3/pl unknown
- 2005-03-21 WO PCT/US2005/009583 patent/WO2005090407A1/en active Application Filing
- 2005-03-21 DK DK05732383.4T patent/DK1735348T3/da active
- 2005-03-21 ES ES05732383T patent/ES2387809T3/es not_active Expired - Lifetime
- 2005-03-21 JP JP2007504185A patent/JP4734319B2/ja not_active Expired - Lifetime
- 2005-03-21 CN CN201210509997.4A patent/CN103007279B/zh not_active Expired - Fee Related
- 2005-03-21 AU AU2005224267A patent/AU2005224267B2/en not_active Ceased
- 2005-03-21 US US10/593,804 patent/US7598350B2/en not_active Expired - Lifetime
- 2005-03-21 MX MXPA06010715A patent/MXPA06010715A/es active IP Right Grant
-
2012
- 2012-08-06 CY CY20121100704T patent/CY1113037T1/el unknown
-
2016
- 2016-05-20 CY CY2016016C patent/CY2016016I1/el unknown
- 2016-05-31 LU LU93093C patent/LU93093I2/fr unknown
- 2016-06-01 LT LTPA2016020C patent/LTC1735348I2/lt unknown
- 2016-06-14 NL NL300819C patent/NL300819I2/nl unknown
- 2016-06-14 HU HUS1600030C patent/HUS000495I2/hu unknown